Viral pharmacodynamic model for (-)-β-2′,3′-dideoxy-5- fluoro-3′-thiacytidine (emtricitabine) in chronically infected woodchucks

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 3, 2002, Pages 165-176

  Hurwitz, Selwyn J ^a   Tennant, Bud C ^b   Korba, Brent E ^c   Liberman, Irina ^a   Gerin, John L ^c   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antiviral agents; Covaricil; Emtricitabine; Pharmacodynamics; Woodchucks

Indexed keywords

EMTRICITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; HEPATITIS B VIRUS; LIVER CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SERUM; VIRUS INHIBITION; VIRUS LOAD; WOODCHUCK; ANIMAL; ANIMAL DISEASE; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; HALF LIFE TIME; HEPATITIS B; HUMAN; SCIURIDAE; TUMOR CELL LINE; VIROLOGY;

ANIMALS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; MARMOTA; MODELS, BIOLOGICAL; VIRAL LOAD;

EID: 2342631429     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300303     Document Type: Article

References (50)

1. Bonhoefer S, May RM, Shaw GM & Nowak MA (1997). Virus dynamics and drug treatment. Proceedings of the National Academy of Sciences USA 94:6971-6976.
2. Cammack N, Rouse P, Marr CLP, Reid PJ, Boehme RE, Coates JAV, Penn CR & Cameron JM (1992). Cellular metabolism of (-)-enantiomeric 2′-deoxy-3′-thiacytidine. Biochemical Pharmacology 43:2059-2064.
3. Darque A, Valette G, Rousseau F, Wang LH, Sommadossi JP & Zhou XJ (1999). Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 43:2245-2250.
4. Dayneka NL, Garg V & Jusko WJ (1993). Comparison of four basic models of indirect pharmacodynamic response. Journal of Pharmacokinetics and Biopharmaceutics 24:457-478.
5. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Tuttle JV, Miller WH, Condreay L, Averett DR, Schinazi RF & Painter GR (1992). The anti-hepatitis B virus activities,cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxythiolan-5-yl]-cytosine (FTC) Antimicrobial Agents and Chemotherapy 36:2686-2692.
6. Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, Pugh J & Mason WS (1994). Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. Journal of Virology 68:8321-8330.
7. Gabrielson J & Weiner D (1997). Pharmacokinetic and Pharmacodynamic Data Analysis: concepts and applications, pp. 31-57. Stockholm: Swedish Pharmaceutical Press.
8. Gibaldi M & Perrier D (1982). Pharmacokinetics, 2nd edn; pp. 113-144. New York: Marcel Decker.
9. Hermann E, Neumann AU; Schmidt JM & Zeuzem S (2000). Hepatitis C virus kinetics. Antiviral Therapy 5:85-90.
10. Hoong LK, Strange LE, Liotta DC, Koszalka GW, Burns CL &, Schinazi RF (1992). Enzyme-mediated enantioselective preparation of the antiviral agent 2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC) and related compounds. Journal of Organic Chemistry 57:5563-5565.
11. Hurwitz SJ, Tennant BC, Korba BE, Gerin JL & Schinazi RF (1998). Pharmacodynamics of (-)-β-2′,3′-dideoxy-3′-thiacytidine (3TC) in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrobial Agents and Chemotherapy 42:2804-2809.
12. Jusko WJ, Hui C & Ko MS (1994). Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology & Therapeutics 56:406-419.
13. Jusko WJ, Ko HC & Ebling WF (1995). Convergence of direct and indirect pharmacodynamic response models. Journal of Pharmacokinetics and Biopharmaceutics 23:5-8.
14. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J & Mason WS (1994). Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. Journal of Virology 68:5792-5803.
15. Korba BE, Wells F, Tennant BC, Cote PJ & Gerin JL (1987). Lymphoid cells in the spleens of woodchuck hepatitis virus-infected woodchucks are a site of active viral replication. Journal of Virology 61:1318-1324.
16. Korba BE, Schinazi RF, Cote P, Tennant BC & Gerin JL (2000a). Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrobial Agents and Chemotherapy 44:1757-1760.
17. Korba BE, Cote P, Hornbuckle W, Tennant BC & Gerin JL. (2000b). Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175.
18. Krzyzanski W & Jusko WJ (1998). Characterization of pharmacodynamic recession slopes for direct and indirect response models. Journal of Pharmacokinetics and Biopharmaceutics 26:409-437
19. Larkin J, Clayton M, Sun B, Perchonock CE, Morgan JL, Siracusa LD, Michaels FH & Feitelson MA (1999). Hepatitis B virus transgenic mouse model of chronic liver disease. Nature Medicine 5:907-912.
20. Lerma JGG, Schinazi RF, Juodawlkis AS, Soriano V, Lin Y, Tatti K, Rimland D, Folks TM & Heneine W (1999). A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrobial Agents and Chemotherapy 43:264-270.
21. Levy G (1966). Kinetics of pharmacological effect. Clinical Pharmacology & Therapeutics 7:362-367.
22. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S & Perelson AS (2001). Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology 34:1012-1020.
23. Mason WS & Taylor JM (1989). Experimental systems for the study of hepadnavirus and delta virus infections. Hepatology 9:635-645.
24. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Serini D, Morlat P, Journot V, Decazes JM & Chene G (2000). Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 182:599-602.
25. Moore LE, Ascenzi MA, Tennant BC, Shi J, Schinazi RF & Boudinot FD (1997). Stereoselective pharmacokinetics and metabolism of 2′-deoxy-5- fluoro-3′-thiacytidine (FTC) in woodchucks. American Association of Pharmaceutical Scientists (AAPS), Boston, Mass., USA, 2-6 November, Abstract 1233.
26. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S & Locarnini S (1995). The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. Journal of Virology 69:3350-3357.
27. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, and McDade H (1996). Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences USA 93:4398-4402.
28. Novak MA, Bonhoefer S, Shaw GM & May RM (1997). Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. Journal of Theoretical Biology 184:203-217.
29. Novak MA & May RM (2000). Virus Dynamics. Oxford: Oxford University Press.
30. Paff MT, Averett DR, Prus KL, Miller WH & Nelson DJ (1994). Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3- oxathiolan-5-yl]-cytosine in HepG2 derivative 2.215 (Subclone P5A) cells. Antimicrobial Agents and Chemotherapy 38:1230-1238.
31. Phillips AN (1996). Reduction of HIV concentrations during acute infection: independence from a specific immune response. Science 271:497-499
32. Roggendorf M & Tolle TK (1995). The woodchuck, an animal model for hepatitis B virus infection in man. Intervirology 38:100-112.
33. Schinazi RF, McMillan AD, Cannon R, Mathis RM, Lloyd A, Peck LA, Sommadossi J-P, St. Clair M., Wilson J, Furman PA, Painter G, Choi W-B & Liotta DC (1992). Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5- yl]cytosine. Antimicrobial Agents and Chemotherapy 36:2423-2431.
34. Schinazi RF, Gosselin G, Faraj A, Korba BE, Liotta DC, Chu CK, Mathe C, Imbach J-L & Sommadossi J-P (1994). Pure nucleoside enantiomers of β-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrobial Agents and Chemotherapy 38:2172-2174.
35. Schinazi RF, Hough LM, Juodawlkis A, Marion P & Tennant B (1997). Comparative activation of 2¢-deoxycytidine and antiviral oxathiolane cytosine nucleosides by different mammalian liver extracts. Antiviral Research 34:A65.
36. Schinazi RF, Ilan E, Black PL, Yao X & Dagan S (1999). Cell-based and animal models for hepatitis B and C viruses. Antiviral Chemistry and Chemotherapy 10:99-114.
37. Schwartz EJ, Neumann AU, Teixeira AV, Bruggeman LA, Rappaport J, Perelson AS & Klotman PE (2002). Effect of target cell availability on HIV-1 production in vitro. AIDS 16:341-345
38. Seeger C, Summers J & Mason WS (1991). Viral DNA synthesis. Current Topics in Microbiology and Immunology 168:41-60.
39. Seeger C & Mason WS (2000). Hepatitis B virus biology. Microbiology and Molecular Biology Reviews 64:51-58.
40. Shaw T & Locarnini S (1995). Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15:169-184.
41. Shewach DS, Liotta DC & Schinazi RF (1993). Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′- deoxycytidine kinase. Biochemical Pharmacology 45:1540-1543.
42. Sheiner LB & Beal S (1980). Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menton model; routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 8:553-571.
43. Summers J, Smith PM & Horwich AL (1990). Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. Journal of Virology 64:2819-2824.
44. Tennant BC, Baldwin BH, Graham LA, Ascezi MA, Hornbuckle WE, Rowland PH, Tochtov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE & Gerin JL (1998). Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191.
45. Tiollias P, Pourcel C & Dejean A (1985). The hepatitis B virus. Nature 317:489-495.
46. Tsiang M, Rooney JF, Toole JJ & Gibbs CS (1999). Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 24:1863-1869.
47. Verotta D & Sheiner LB (1995). A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. Journal of Pharmacokinetics and Biopharmaceutics 23:1-4.
48. Wagner JG (1968). Kinetics of pharmacological response 1. Proposed relationships between response and drug concentration in the intact animal and man. Journal of Theoretical Biology 20:173-201.
49. Wald JA, Salazar DE, Cheng H & Jusko & WJ (1991). Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. Journal of Pharmacokinetics and Biopharmaceutics 19:521-536.
50. Weissinger J (1998). Utility of kenetic, dynamic, and metabolic data in monoclonal pharmacology/toxicology studies. In: Integration of pharmacokinetics, pharmodynamics, and toxicokinetics in rational drug development, pp. 15-22. Edited by A Yacobi, JP Skelley, VP Shah & LZ Benet. New York & London: Plenum.